









市场行情
/
股票
/
nasdaq-inva
/

Innoviva Inc

INVA

18.660USD

+0.030+0.16%

交易中（美东）报价延迟15分钟

1.17B总市值

亏损市盈率 TTM



Innoviva Inc

18.660

+0.030+0.16%

概览公司财务

Innoviva, Inc. 是一家多元化控股公司，拥有一系列专利和其他医疗资产。该公司的专利组合包括与葛兰素集团有限公司 (GSK) 合作的呼吸系统资产，包括 RELVAR/BREO ELLIPTA（糠酸氟替卡松/维兰特罗，FF/VI）和 ANORO ELLIPTA（溴化乌美溴铵/维兰特罗，UMEC/VI）。根据长效β2激动剂 (LABA) 合作协议，该公司有权从 GSK 获得 RELVAR/BREO、ELLIPTA 销售的专利使用费。该公司的产品包括 GIAPREZA（血管紧张素 II），获批用于增加感染性或其他分布性休克成人患者的血压，以及 XERAVA（埃拉环素），获批用于治疗成人复杂的腹腔内感染。第三款产品 XACDURO（以前称为舒巴坦-杜洛巴坦或 SUL-DUR）获批用于治疗成人不动杆菌引起的医院内获得性和呼吸机相关性肺炎。开发产品线包括佐利氟达星，这是一种用于治疗单纯性淋病的试验性药物，目前处于 III 期临床试验阶段。

公司简介

公司代码INVA

公司名称Innoviva Inc

上市日期Oct 05, 2004

CEOMr. Pavel Raifeld

员工数量127

证券类型Ordinary Share

年结日Oct 05

公司地址1350 Old Bayshore Highway

城市BURLINGAME

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编94010

电话16502389600

网址https://www.inva.com/

公司代码INVA

上市日期Oct 05, 2004

CEOMr. Pavel Raifeld

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Mark A. Dipaolo, Esq.

Chairman of the Board

130.71K

+10.18%

Dr. Sarah J. Schlesinger, M.D.

Lead Independent Director

130.71K

+10.18%

Dr. Sapna Srivastava, Ph.D.

Independent Director

44.10K

+11.98%

Ms. Marianne Y. Zhen, CPA

Chief Accounting Officer

27.71K

-3.46%

Mr. Pavel Raifeld

Chief Executive Officer

12.60K

+8.03%

Mr. Stephen Basso

Chief Financial Officer

4.63K

+31.73%

Mr. Jules A. Haimovitz

Independent Director

Dr. Odysseas D. Kostas, M.D.

Director

Mr. Derek A Small

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Mark A. Dipaolo, Esq.

Chairman of the Board

130.71K

+10.18%

Dr. Sarah J. Schlesinger, M.D.

Lead Independent Director

130.71K

+10.18%

Dr. Sapna Srivastava, Ph.D.

Independent Director

44.10K

+11.98%

Ms. Marianne Y. Zhen, CPA

Chief Accounting Officer

27.71K

-3.46%

Mr. Pavel Raifeld

Chief Executive Officer

12.60K

+8.03%

Mr. Stephen Basso

Chief Financial Officer

4.63K

+31.73%

收入明细

FY2025Q1

FY2024

暂无数据

地区USD

名称

营收

占比

United States

88.63M

0.00%

业务

地区

暂无数据

股东统计

更新时间: 5月17日周六

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.12%

The Vanguard Group, Inc.

10.01%

Dimensional Fund Advisors, L.P.

7.42%

Renaissance Technologies LLC

7.26%

Putnam Investment Management, L.L.C.

6.21%

Other

55.98%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.12%

The Vanguard Group, Inc.

10.01%

Dimensional Fund Advisors, L.P.

7.42%

Renaissance Technologies LLC

7.26%

Putnam Investment Management, L.L.C.

6.21%

Other

55.98%

股东类型

持股股东

占比

Investment Advisor

45.92%

Investment Advisor/Hedge Fund

33.15%

Hedge Fund

23.37%

Research Firm

6.09%

Pension Fund

1.54%

Individual Investor

1.06%

Bank and Trust

0.43%

Sovereign Wealth Fund

0.19%

Venture Capital

0.10%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

494

70.23M

111.87%

-7.08M

2025Q1

503

69.52M

110.75%

-9.29M

2024Q4

492

73.18M

116.75%

-6.44M

2024Q3

487

75.41M

120.47%

-5.51M

2024Q2

492

75.89M

121.41%

-5.03M

2024Q1

502

75.85M

119.80%

-4.18M

2023Q4

494

74.97M

116.88%

-1.82M

2023Q3

486

71.34M

109.51%

-8.23M

2023Q2

482

72.90M

111.23%

-6.11M

2023Q1

482

72.87M

106.90%

-10.58M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

8.24M

13.12%

-285.10K

-3.34%

Mar 31, 2025

The Vanguard Group, Inc.

6.28M

10.01%

-16.60K

-0.26%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

4.66M

7.42%

-259.73K

-5.28%

Mar 31, 2025

Renaissance Technologies LLC

4.56M

7.26%

+295.50K

+6.93%

Mar 31, 2025

Putnam Investment Management, L.L.C.

3.90M

6.21%

-462.44K

-10.61%

Mar 31, 2025

Sarissa Capital Management, L.P.

2.82M

4.49%

-4.46M

-61.30%

Mar 31, 2025

State Street Global Advisors (US)

2.36M

3.77%

-94.90K

-3.86%

Mar 31, 2025

Systematic Financial Management, L.P.

2.07M

3.3%

+42.18K

+2.08%

Mar 31, 2025

Millennium Management LLC

1.68M

2.67%

+1.28M

+318.37%

Mar 31, 2025

American Century Investment Management, Inc.

1.68M

2.67%

+251.38K

+17.65%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Invesco Pharmaceuticals ETF

2.84%

ETC 6 Meridian Small Cap Equity ETF

2.56%

First Trust Horizon Managed Vol Small/Mid ETF

2.39%

SPDR S&P Pharmaceuticals ETF

2.04%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.44%

Invesco S&P SmallCap Low Volatility ETF

1.25%

Acquirers Small and Micro Deep Value ETF

0.94%

VictoryShares US Small Mid Cap Value Momentum ETF

0.82%

Invesco S&P SmallCap Health Care ETF

0.79%

Pacer US Small Cap Cash Cows Growth Leaders ETF

0.76%

Invesco Pharmaceuticals ETF

占比2.84%

ETC 6 Meridian Small Cap Equity ETF

占比2.56%

First Trust Horizon Managed Vol Small/Mid ETF

占比2.39%

SPDR S&P Pharmaceuticals ETF

占比2.04%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.44%

Invesco S&P SmallCap Low Volatility ETF

占比1.25%

Acquirers Small and Micro Deep Value ETF

占比0.94%

VictoryShares US Small Mid Cap Value Momentum ETF

占比0.82%

Invesco S&P SmallCap Health Care ETF

占比0.79%

Pacer US Small Cap Cash Cows Growth Leaders ETF

占比0.76%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

KeyAI

